INDP Earnings — Indaptus Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
INDP — Indaptus Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$1.76
Market Cap$199.3M
P/E—
52W Range$0.92 – $19.91
Next Earnings2026-08-12
About Indaptus Therapeutics, Inc. Common Stock
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
